Advertisement
| autoimmune therapy for melanoma: Cutaneous Melanoma , |
| autoimmune therapy for melanoma: Drug-Induced Liver Injury , 2019-07-13 Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series |
| autoimmune therapy for melanoma: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| autoimmune therapy for melanoma: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| autoimmune therapy for melanoma: Immune Checkpoint Inhibitors in Cancer Fumito Ito, Marc Ernstoff, 2018-09-03 Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource. |
| autoimmune therapy for melanoma: Cancer and Autoimmunity M.E. Gershwin, Yehuda Shoenfeld, 2000-03-27 Of the two disciplines in parallel development for two decades, tumor immunology and transplantation immunology, the latter has thrived and has led to some of the most critical discoveries in immunobiology. The former continues to thwart both scientists and clinicians alike.The goal of immunologists in modern day research is to develop a simple and effective means to manipulate cancer in vivo, possibly encompassing several venues: identifying a phenotypic marker and the use of either active or passive immunization; include the use of passive reagents carrying warheads to selectively destroy cancer cells; or altering the basic process of cell survival.This excellent multidiscipline-authored volume presents a theme which has not been well described before. The papers include both basic and clinical science and range from sophisticated molecular biology to little more than phenomenology (e.g. the increased association of cancer in some autoimmune diseases and increased presentation of autoimmune phenomena in malignant condition). This, however, is state-of-the-art.This collection of themes will be of use not only to bench scientists, but also to clinicians who treat patients. The book represents progress at the cutting edge of this discipline, and points the way to further developments in the black box of immunology. |
| autoimmune therapy for melanoma: Hospitalist Neurology Martin A. Samuels, 1999 Hospitalist Neurology, in the highly regarded Blue Books of Practical Neurology series, focuses on the clinical practice of in-patient neurology as well as the neurologic sequelae of non-neurologic conditions of hospitalized patients. It is meant to provide consulting hospital-based neurologists with a rational approach to evaluating neurological problems in a busy general hospital. |
| autoimmune therapy for melanoma: Advancing Healthcare Through Personalized Medicine Priya Hays, 2021-09-27 This book provides a unique perspective on the biomedical and societal implications of personalized medicine and how it helps to mitigate the healthcare crisis and rein in ever-growing expenditure. It introduces the reader to the underlying concepts at the heart of personalized medicine. An innovative second edition, this book functions as an update to the successful first edition to include new, state-of-the-art information and advancements in the fast-paced field of personalized medicine. Chapters examine pharmacogenomics, targeted therapies, individualized diagnosis and treatment, and cancer immunotherapies. The book also features an essential discussion on how the advent of genomic technologies gives clinicians the capability to predict and diagnose disease more efficiently and offers a detailed up-to-date compilation of clinical trials in cancer leading to breakthrough therapies. The book also addresses the impact of Big Data on personalized medicine and the newfound applications of digital health and artificial intelligence. A work that advocates for a patient-centered approach, Advancing Healthcare Through Personalized Medicine, Second Edition is an invaluable text for clinicians, healthcare providers, and patients. |
| autoimmune therapy for melanoma: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| autoimmune therapy for melanoma: Encyclopedia of Cancer Manfred Schwab, 2008-09-23 This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely. |
| autoimmune therapy for melanoma: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| autoimmune therapy for melanoma: Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2016-12-10 Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop. |
| autoimmune therapy for melanoma: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| autoimmune therapy for melanoma: Immune Surveillance Richard T. Smith, 2012-12-02 Immune Surveillance deals with the issues regarding tumor immunology and surveillance, in which the central theme is all about the life span of the mammalian host that is depleted by the environment with mutagenic agents and solutions. The book is divided into six chapters. It includes discussions on the organization and modulation of cell membrane receptors, as well as the origin and expression of membrane antigens. It also covers the topics on the triggering mechanisms for and effector mechanisms activated by the cellular recognition. These topics analyze and evaluate alternatives for the recognition and destruction mechanisms in the knowledge of cell cooperation and requirements for immune recognition. A chapter provides discourse on a solution for the paradox of thriving tumors based on the demonstrable in vitro host immunity. Another discusses the generation of antibody diversity and the theory of self-tolerance. The last chapter explains the evaluation of the evidence for immune surveillance. This reference will be invaluable to those who specialize in immunology. |
| autoimmune therapy for melanoma: The History of Oncology D. J. Th. Wagener, 2009-07-13 ‘The story of oncology is not only fascinating but also contains many accounts of dead ends, chance discoveries, illusions, mistakes and disappointments alongside the few successes.’These words are taken from the introduction to this book. The author, professor emeritus of Medical Oncology, reviews all aspects of the problem of cancer from a historical perspective, from the oldest existing records to the latest scientific and medical advances. It will interest the many people engaged in the treatment of cancer to read how the current therapeutic methods came about, and the book may also provide inspiration for cancer researchers, and for all those directly or indirectly involved with cancer. The layman looking for background information on a particular treatment may find it useful too. The various chapters can be read independently. A glossary and a few explanatory diagrams augment the text.This book grew out of an invitation the author received to lecture on the history of oncology. During his background reading, he discovered that there was no single volume dealing with the entire history of the subject. Fortunately, however, a great deal of information could be found here and there in the literature. As he read, he was struck by the fascinating stories behind many discoveries, and felt impelled to put them together in a single comprehensive account. The results of his labors are presented in this remarkable volume.The author, Prof. D.J.Th. (Theo) Wagener, was head of the department of Medical Oncology at the Radboud University Nijmegen Medical Centre in the Netherlands from 1982 to 2001, chairman of the Educational Committee of the European Society of Medical Oncology (ESMO), a member of the Educational Committee of the American Society of Clinical Oncology (ASCO) and a member of various international scientific working groups, mainly of the European Organization for Research and Treatment of Cancer (EORTC). |
| autoimmune therapy for melanoma: Cancer Immune Therapy Gernot Stuhler, Peter Walden, 2002-12-03 Cure or life with cancer? What can be achieved by cancer immune therapy? The past decade has seen substantial advancements in tumor immunology. Much of the new knowledge has been translated into new strategies for cancer treatment and into clinical trials. Some of these trials herald future breakthroughs, others have been disappointing and have prompted intensive search for alternatives.Major contributors to the field summarize the knowledge on the molecular and cellular mechanisms of tumorigenesis, critically review the instruments of the immune system that might be exploited for therapy, and discuss the clinical experiences with the different immune therapy concepts. Researchers in the fields of immunology, tumor biology and medicine will highly appreciate this up-to-date volume for evaluating future research activities. |
| autoimmune therapy for melanoma: Selective Immunosuppression Luciano Adorini, 1995 |
| autoimmune therapy for melanoma: Endocrine Immunology W. Savino, F. Guaraldi, 2017-02-28 In the last decades, several in vitro and in vivo studies have revealed the existence of a very complex network between the neuroendocrine and immune system. Important molecular mechanisms underlying these interactions, in both physiological and pathological conditions, have also been described. Indeed, hormones play a pivotal role in the development and functional regulation of the immune system – both innate and acquired responses. Immune system cells present specific hormone receptors and themselves produce some hormones, thus influencing hormone secretion. More recently, the modulation of hormone secretion has been attempted for treating associated autoimmune disorders, further supporting the strong interplay between the endocrine and immune system. Distinguished experts, who have published extensively in their fields, have contributed comprehensive chapters to this volume. The focus is on the various aspects of endocrine-neuro-immune connections, providing an updated panorama - from basics to clinical applications - of current knowledge and still debated issues. |
| autoimmune therapy for melanoma: Oncology in the Precision Medicine Era Ravi Salgia, 2019-12-17 This volume comprehensively reviews oncology in the precision medicine era of personalized care, latest developments in the field, and indications and clinical trials for the treatment of cancer with targeted therapies, immunotherapy, and epigenetic modulators. It thoroughly addresses concerns of various types of cancers including cancers of the head and neck, lung, colon, esophagus, bladder, pancreas, and breast; melanoma; multiple myeloma; hepatocellular carcinoma; renal cell carcinoma; and sarcomas. It is organized and written in a format that is easy to follow for both clinicians and non-clinical scientists interested in personalized medicine. Chapters cover the identification of the clinical problem and summary of recent findings, tumor biology and heterogeneity, genomics, examples of simple and complex cases, biological pathways, future clinical trials, and financial considerations. Oncology in the Precision Medicine Era: Value-Based Medicine will serve as a useful resource for medical oncologists and healthcare providers tailoring medicine to the needs of the individual patient, from prevention and diagnosis to treatment and follow up. |
| autoimmune therapy for melanoma: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Kulmira Nurgali, R. Thomas Jagoe, Raquel Abalo, 2018-06-12 Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them. |
| autoimmune therapy for melanoma: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| autoimmune therapy for melanoma: Comorbidity in Rheumatic Diseases Yasser El Miedany, 2017-08-24 This book explores comorbidity in patients with rheumatic diseases and details both care and treatment options in standard clinical practice. Patients with rheumatic diseases are clinically complex, and the interplay of their disease activity with associated conditions may lead to increased morbidity and mortality. Recently there have been major advances in the management of rheumatic diseases, however, without addressing the potential comorbid conditions, including cardiovascular disease; pulmonary disease; and depression; outcomes remain poor. With its 19 chapters, covering the management of major rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus , and osteoarthritis), potential comorbidities and treatment recommendations, as well as possible interactions between conditions; this book addresses the gap between textbook medicine and day to day patients' care. Authors also discuss the new hot issue of the comorbidity index, comparing the standard tools to the recently developed indices and how they can assist the rheumatologists in determining disease burden, prognosis, and comorbidity probability. This book is an ideal clinical guide and reference that enables rheumatologists, internal medicine physicians, and residents to address the full clinical expression of these rheumatic diseases with views towards prevention or early management of comorbid conditions. |
| autoimmune therapy for melanoma: Epidemiology of Endocrine Tumors Jahangir Moini, Craig Badolato, Raheleh Ahangari, 2021-03-03 Epidemiology of Endocrine Tumors brings current data and clinical research into one source for a multidisciplinary audience. The book discusses the prevalence, incidence, etiology, pathology, diagnosis and treatment of various endocrine tumors. With clear and focused writing, it is essential reading for healthcare professionals, endocrinologists, oncologists, and public health professionals. Users will be able to bridge the knowledge gap that exists in the comprehensive coverage surrounding the epidemiology of endocrine tumors. Globally, the prevalence and incidence of endocrine tumors is high. This audience needs a treatise where they can gain a broad overview of endocrine tumors with a focus on epidemiology. - Supplies information about the epidemiology of various endocrine tumors, both benign and malignant, to endocrinologists, oncologists and related health care professionals - Focuses on the impact upon costs and patient deaths due to complications of these tumors - Describes how endocrine tumors affect various age groups and ethnicities, discussing the prevention of endocrine tumors - Presents chapters on Cancer Problem, Specific Endocrine Tumors, Prevention, Detection and Diagnosis, and Treatment of Endocrine Tumors - Provides review questions with an answer key and detailed glossary |
| autoimmune therapy for melanoma: Uveal Melanoma Eric H. Bernicker, 2021-08-03 This book provides a comprehensive examination of uveal melanoma, a rare neoplasm that carries a very high mortality and whose natural history makes it fairly unique among adult tumors. Split into three sections, this book explores the basic science behind the disease and inherited genetic syndromes that predispose some patients, as well as the pathology and use of gene expression profiling to determine risk of recurrence. It also focuses on the management of the primary tumor in the eye, including surgical intervention and lesion imaging. Elucidating treatment options for metastatic disease, the book reviews chemotherapy agents and immunotherapy approaches, as well as liver-directed therapies, cellular therapies, and various treatments after primary treatment but before the development of metastases. Uveal Melanoma: Biology and Management is the most up-to-date and comprehensive text devoted solely to this disease and will be useful to medical oncologists, ophthalmologists, radiation therapists, interventional radiologists, pathologists, molecular biologists and immunology researchers, as well as trainees in those fields. |
| autoimmune therapy for melanoma: Radiation Therapy for Skin Cancer Armand B Cognetta, William M. Mendenhall, 2013-06-13 Photon Radiation Therapy for Skin Malignancies is a vital resource for dermatologists interested in radiation therapy, including the physics and biology behind treatment of skin cancers, as well as useful and pragmatic formulas and algorithms for evaluating and treating them. Dermatology has always been a field that overlaps multiple medical specialties and this book is no exception, with its focus on both dermatologists and radiation oncologists. It is estimated that between 2010 and 2020, the demand for radiation therapy will exceed the number of radiation oncologists practicing in the U.S. tenfold, which could profoundly affect the ability to provide patients with sufficient access to treatment. Photon Radiation Therapy for Skin Malignancies enhances the knowledge of dermatologists and radiation oncologists and presents them with the most up-to-date information regarding detection, delineation and depth determination of skin cancers, and appropriate biopsy techniques. In addition, the book also addresses radiation therapy of the skin and the skin’s reactions to radiation therapy. |
| autoimmune therapy for melanoma: Improving Outcomes in Oral Cancer Deepak Kademani, 2019-11-13 This book brings together experts in the field of maxillofacial and head and neck oncology to provide a comprehensive clinical and translational update on oral cancer that focuses especially on prognosis. Readers will find up-to-date information on disease staging and the pathological, genetic, and surgical factors that affect patient outcomes. Individual chapters describe the most recent advances in radiotherapy, chemotherapy, and immunotherapy, again with careful analysis of the treatment-related factors relevant to response and survival. Management of premalignant lesions and risk factors for malignant transformation are discussed, and the latest knowledge on chemoprevention is presented. Further topics to be addressed include reconstruction of oral cancer defects, salvage options in the event of recurrence, and the prediction of quality of life following treatment. The book will be of value to all clinicians who care for patients with oral cancer in their everyday practice. |
| autoimmune therapy for melanoma: Immunological Surveillance Macfarlane Burnet, 2014-05-17 Immunological Surveillance |
| autoimmune therapy for melanoma: Autoimmune Reactions Sudhir Paul, 2012-10-10 Autoimmune Reactions tackles fundamental questions about how the immune system can destroy invading microbial pathogens without causing damage to itself and other self systems. The authoritative experts writing here explore the mechanistic aspects of such autoimmune diseases as lupus, rheumatoid arthritis, diabetes, and autoimmune thyroid disease, and where possible delineate how malfunctioning immunological mechanisms can lead to clinical symptoms. They also discusses possible general mechanisms of autoimmune disease-e.g., molecular mimicry and dysfunctional antigen presentation-and their current limitations as unifying explanations of the diseases described. The book illustrates the type of thinking and research that should eventually permit development of palliatives and cures for autoimmune diseases. |
| autoimmune therapy for melanoma: Immunotherapy of Melanoma Anand Rotte, Madhuri Bhandaru, 2016-12-19 This book focusses on the different types of immunotherapeutics that are currently being used and developed for the treatment of melanoma. In recent years, immunotherapy has revolutionized the treatment of metastatic melanoma and other types of cancer. Discussing treatment options for melanoma and the success of immunotherapy along with the challenges of immunotherapy, this book covers epidemiology, susceptibility genes, and treatment recommendations from Society for Immunotherapy of Cancer, as well as immune based therapies such as aldesleukin, Intron-A, Sylatron, Yervoy, Opdivo, Keytruda, Imlygic, DC vaccines and adoptive cell therapy. The detailed information included on the key immune cells involved in anti-tumor immune response and immune-inhibitory mechanisms in tumor microenvironment will aid the understanding of tumor immunology. Both academic as well as industry-based researchers, developing novel anti-cancer therapies, will also benefit from the details of promising molecular targets and immunotherapeutic strategies under investigation. With 132 illustrations including synopsis tables for important information, over 1200 references (majority of which are openly accessible) and details of more than 150 ongoing clinical trials, this book is a valuable source of information for health care providers as well as cancer biologists interested in learning about melanoma and the significant advances made by immunotherapy. |
| autoimmune therapy for melanoma: Polymyalgia Rheumatica and Giant Cell Arteritis Jozef Rovensky, Burkhard F. Leeb, Howard Bird, Viera Štvrtinová, Richard Imrich, 2010-05-06 In the present monograph, we offer current insights into polymyalgia rheumatica and giant cell arthritis. Both diseases are typical for advanced age, and their incidences increase with aging. Both diseases are a center point of interest not only for rheu- tologists, gerontologists, ophthalmologists or neurologists, but also for general prac- tioners. Early diagnosis and rapid treatment, mainly with glucocorticoids can save one of the most precious senses-vision. Damage to other organs (heart, aorta, co- nary arteries, liver, lungs, kidneys), which are supplied by the arteries affected by ischemic syndrome in the setting of giant cell arthritis, has serious consequences as well. Late diagnosis of giant cell arthritis can have fatal consequences for affected patients. It is a matter of fact that the human population is aging. Therefore, more attention has to be paid not only to diagnosis, clinical course and treatment of rheumatic d- eases in elderly, but also to their genetic, immunologic, endocrinologic, chronobiologic mechanisms, and state-of-the-art diagnostic modalities. I am convinced that the int- disciplinary research of the diseases will allow us to diagnose and treat the rheumatic diseases even faster and more effectively in the future. |
| autoimmune therapy for melanoma: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| autoimmune therapy for melanoma: The Breakthrough Charles Graeber, 2015-12-01 Follow along as this New York Times bestselling author details the astonishing scientific discovery of the code to unleashing the human immune system to fight in this captivating and heartbreaking book (The Wall Street Journal). For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold? As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses -- tricks that scientists have only recently discovered and learned to defeat. The result is what many are calling cancer's penicillin moment, a revolutionary discovery in our understanding of cancer and how to beat it. In The Breakthrough, New York Times bestselling author of The Good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step -- harnessing the wealth of new information to create modern and more effective patient therapies -- is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease. Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history. |
| autoimmune therapy for melanoma: Oral, Head and Neck Oncology and Reconstructive Surgery - E-Book R. Bryan Bell, Peter A. Andersen, Rui P. Fernandes, 2017-08-25 Oral, Head and Neck Oncology and Reconstructive Surgery is the first multidisciplinary text to provide readers with a system for managing adult head and neck cancers based upon stage. Using an evidence-based approach to the management and treatment of a wide variety of clinical conditions, the extensive experience of the author and contributors in head and neck surgery and oncology are highlighted throughout the text. This includes computer aided surgical simulation, intraoperative navigation, robotic surgery, endoscopic surgery, microvascular reconstructive surgery, molecular science, and tumor immunology. In addition, high quality photos and illustrations are included, which are easily accessible on mobile devices. - Management protocols and outcomes assessment provide clear guidelines for managing problems related to adult head and neck oncology and reconstructive surgery. - State-of-the art guidance by recognized experts details current techniques as well as technological advances in head and neck/cranio-maxillofacial surgery and oncology. - Evidence-based content details the latest diagnostic and therapeutic options for treating a wide-variety of clinical problems with an emphasis on surgical technique and outcomes. - Multidisciplinary approach reflects best practices in managing head and neck oncology and cranio-maxillofacial surgery. - 900 highly detailed images clearly demonstrate pathologies and procedures. - Designed for the modern classroom which lets you access important information anywhere through mobile tablets and smart phones. |
| autoimmune therapy for melanoma: Facing Immunotherapy Justine Cohen, Leyre Zubiri, Kerry Reynolds, 2019-12-18 Facing Immunotherapy is for anyone whose life is affected by cancer and who is considering (or is receiving) immunotherapy. Written by leading physicians in their fields, Facing Immunotherapy combines top-tier medical information and compassionate counsel on the use and tolerability of immunotherapies, with a caring and sensible approach to the emotional aspects of living with cancer treatment and its complications. This book provides easily readable and trustworthy information, which is divided amongst twenty-six chapters that ask and answer pertinent questions about immunotherapy and its medical, surgical, and psychiatric/psychological components. A glossary of terms provides important background information to readers (e.g., about the disease, nutrition, diet, exercise, and risk-reduction); online resources and references are also offered. Each chapter is accompanied by selected reference and internet resources as well as illustrations and photographs. |
| autoimmune therapy for melanoma: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| autoimmune therapy for melanoma: The Gerson Therapy Charlotte Gerson, Morton Walker, 2001 Offers a nutritional program that utilizes the healing powers of organic fruits and vegetables to reverse the effects of cancer and other illnesses. |
| autoimmune therapy for melanoma: Antineoplastons Burzynski Research Institute, 1988 |
| autoimmune therapy for melanoma: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| autoimmune therapy for melanoma: Lymphocyte Activation L.E. Samelson, H. Renz, 1994 |
| autoimmune therapy for melanoma: Autoimmune Endocrinopathies Robert Volpe, 2014-01-15 |
The first and only FDA-approved T cell therapy for advanced …
AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking …
Immune checkpoint inhibitors in melanoma - The Lancet
PD-1 inhibitors are now an established standard of care as adjuvant therapy in high-risk resected stage III or IV melanoma. Neoadjuvant checkpoint inhibition for resectable stage III melanoma, …
Immunotherapy in Melanoma: Use in Patients with …
•Review the current place in practice for immunotherapy in melanoma •Discuss the use of immunotherapy in patients with autoimmune conditions. Objectives. accc-iclio.org. Systemic …
Beyond Checkpoint Inhibition: Keeping Therapeutic Options …
Apr 15, 2025 · mobilizing monoclonal TCRs against cancer, are poised to be the next breakthrough in therapeutics for metastatic melanoma. These novel therapies provide the …
Combination anti-PD1 and ipilimumab therapy in patients …
We sought to establish the safety and eficacy of combination immunotherapy for patients with advanced melanoma and pre- existing autoimmune diseases.
TIGIT, a novel immune checkpoint therapy for melanoma
In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 …
Programmed cell death protein-1 (PD-1) inhibitor therapy in …
Here, we summarise the experience from seven German skin cancer centres and assess patients undergoing PD-1i therapy for metastatic melanoma with regard to flare of preexisting …
Anti-PD-1 therapy in patients with advanced melanoma and …
The results of this study suggest that anti-PD-1 antibodies have efficacy in metastatic melanoma patients with preexisting autoimmune disorders, and in patients with major irAEs with ipilimumab.
Autoimmune Therapy For Melanoma
The autoimmune destruction of melanocytes (vitiligo) has been associated with enhanced survival in melanoma patients, and melanoma-associated vitiligo is the best-studied examples of the …
Ipilimumab in metastatic melanoma patients with pre-existing …
Due to their higher eficacy, PD-1-antibodies or the combination of nivolumab plus ipilimumab replaced ipilimumab monotherapy in the front-line treatment of metastatic melanoma. …
Pembrolizumab and Ipilimumab as Second-Line Therapy for …
Jun 17, 2021 · In a multicenter retrospective study, Zimmer et al23 evaluated patients with advanced melanoma who had progressed on prior PD-1 monotherapy and were treated with …
Nivolumab and Relatlimab (Opdualag) - CDA-AMC
There is an unmet medical need for an additional novel immune checkpoint inhibitor combination therapy in metastatic melanoma which can be used regardless of BRAF mutation status.
Immunotherapies for autoimmune diseases - Nature
Although immunotherapies for treating cancer and those for treating autoimmunity seek opposite effects on the immune system — in cancer, to prime or enhance immune responses against …
Second-line immunotherapy in patients with metastatic …
During the past decade, checkpoint inhibitor immunotherapy has improved disease control for patients with advanced melanoma, often resulting in durable responses, with survival …
Autoimmune diseases and immune-checkpoint inhibitors for …
In addition, we challenge the exclusion from ICI therapy for patients with cancer and active ADs and propose the implementation of an international registry to study such novel strategies in a …
Autoimmune Hemolytic Anemia as a Complication of …
Nov 7, 2016 · Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al.: BMC Med 2016;14:20], …
Autoimmune comorbidities in patients with metastatic …
This is the first study, to our best knowledge, that examined the prevalence of autoimmune diseases in patients with metastatic melanoma, which is important as newer treatment options …
Preexisting Autoimmune Disease: Implications for Immune
This review discusses the commonalities between clinical autoimmune diseases and ICI-induced immunotherapy-related ad-verse events, and summarizes the existing case series that …
Gene signature from cutaneous autoimmune diseases …
Our data provide an understanding of the immune‐related characteristics and diferential gene expression patterns in autoimmune skin diseases, which may represent promising targets for …
The many faces of autoimmune-mediated melanocyte …
The present review aims at providing an overview of autoimmune-mediated melanocyte destruction that can appear in association with melanoma, from the risk of developing …
The first and only FDA-approved T cell therapy for advanced …
AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking …
Immune checkpoint inhibitors in melanoma - The Lancet
PD-1 inhibitors are now an established standard of care as adjuvant therapy in high-risk resected stage III or IV melanoma. Neoadjuvant checkpoint inhibition for resectable stage III melanoma, …
Immunotherapy in Melanoma: Use in Patients with …
•Review the current place in practice for immunotherapy in melanoma •Discuss the use of immunotherapy in patients with autoimmune conditions. Objectives. accc-iclio.org. Systemic …
Beyond Checkpoint Inhibition: Keeping Therapeutic Options …
Apr 15, 2025 · mobilizing monoclonal TCRs against cancer, are poised to be the next breakthrough in therapeutics for metastatic melanoma. These novel therapies provide the potential for long …
Combination anti-PD1 and ipilimumab therapy in patients with …
We sought to establish the safety and eficacy of combination immunotherapy for patients with advanced melanoma and pre- existing autoimmune diseases.
TIGIT, a novel immune checkpoint therapy for melanoma
In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 inhibitors …
Programmed cell death protein-1 (PD-1) inhibitor therapy in …
Here, we summarise the experience from seven German skin cancer centres and assess patients undergoing PD-1i therapy for metastatic melanoma with regard to flare of preexisting …
Anti-PD-1 therapy in patients with advanced melanoma and …
The results of this study suggest that anti-PD-1 antibodies have efficacy in metastatic melanoma patients with preexisting autoimmune disorders, and in patients with major irAEs with ipilimumab.
Autoimmune Therapy For Melanoma
The autoimmune destruction of melanocytes (vitiligo) has been associated with enhanced survival in melanoma patients, and melanoma-associated vitiligo is the best-studied examples of the linkage …
Ipilimumab in metastatic melanoma patients with pre-existing …
Due to their higher eficacy, PD-1-antibodies or the combination of nivolumab plus ipilimumab replaced ipilimumab monotherapy in the front-line treatment of metastatic melanoma. However, …
Pembrolizumab and Ipilimumab as Second-Line Therapy for …
Jun 17, 2021 · In a multicenter retrospective study, Zimmer et al23 evaluated patients with advanced melanoma who had progressed on prior PD-1 monotherapy and were treated with …
Nivolumab and Relatlimab (Opdualag) - CDA-AMC
There is an unmet medical need for an additional novel immune checkpoint inhibitor combination therapy in metastatic melanoma which can be used regardless of BRAF mutation status.
Immunotherapies for autoimmune diseases - Nature
Although immunotherapies for treating cancer and those for treating autoimmunity seek opposite effects on the immune system — in cancer, to prime or enhance immune responses against …
Second-line immunotherapy in patients with metastatic …
During the past decade, checkpoint inhibitor immunotherapy has improved disease control for patients with advanced melanoma, often resulting in durable responses, with survival measured …
Autoimmune diseases and immune-checkpoint inhibitors for …
In addition, we challenge the exclusion from ICI therapy for patients with cancer and active ADs and propose the implementation of an international registry to study such novel strategies in a …
Autoimmune Hemolytic Anemia as a Complication of …
Nov 7, 2016 · Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al.: BMC Med 2016;14:20], metastatic …
Autoimmune comorbidities in patients with metastatic …
This is the first study, to our best knowledge, that examined the prevalence of autoimmune diseases in patients with metastatic melanoma, which is important as newer treatment options for …
Preexisting Autoimmune Disease: Implications for Immune
This review discusses the commonalities between clinical autoimmune diseases and ICI-induced immunotherapy-related ad-verse events, and summarizes the existing case series that describes …
Gene signature from cutaneous autoimmune diseases …
Our data provide an understanding of the immune‐related characteristics and diferential gene expression patterns in autoimmune skin diseases, which may represent promising targets for …
The many faces of autoimmune-mediated melanocyte …
The present review aims at providing an overview of autoimmune-mediated melanocyte destruction that can appear in association with melanoma, from the risk of developing melanoma to …
